We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
47 hedge funds and large institutions have $50.2M invested in Corvus Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
71% more call options, than puts
Call options by funds: $111K | Put options by funds: $65K
58% more capital invested
Capital invested by funds: $31.9M → $50.2M (+$18.4M)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
7.61% more ownership
Funds ownership: 36.5% → 44.11% (+7.6%)
0% more funds holding
Funds holding: 47 → 47 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Holders
47
Holders Change
–
Holders Change %
0%
% of All Funds
0.68%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
7
Increased
12
Reduced
10
Closed
7
Calls
$111K
Puts
$65K
Net Calls
+$46K
Net Calls Change
+$40K
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.1M |
| 2 |
SC
Samlyn Capital
New York
|
+$7.03M |
| 3 |
Millennium Management
New York
|
+$338K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$293K |
| 5 |
Morgan Stanley
New York
|
+$179K |
